Bone Effects of Biologic Drugs in Rheumatoid Arthritis
Open Access
- 20 June 2013
- journal article
- review article
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2013, 1-7
Abstract
Biologic agents used in the treatment of rheumatoid arthritis (RA) are able to reduce both disease activity and radiographic progression of joint disease. These drugs are directed against several proinflammatory cytokines (TNFα, IL-6, and IL-1) which are involved both in the pathogenesis of chronic inflammation and progression of joint structural damage and in systemic and local bone loss typically observed in RA. However, the role of biologic drugs in preventing bone loss in clinical practice has not yet clearly assessed. Many clinical studies showed a trend to a positive effect of biologic agents in preventing systemic bone loss observed in RA. Although the suppression of inflammation is the main goal in the treatment of RA and the anti-inflammatory effects of biologic drugs exert a positive effect on bone metabolism, the exact relationship between the prevention of bone loss and control of inflammation has not been clearly established, and if the available biologic drugs against TNFα, IL-1, and IL-6 can exert their effect on systemic and local bone loss also through a direct mechanism on bone cell metabolism is still to be clearly defined.Keywords
This publication has 62 references indexed in Scilit:
- The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid ArthritisArthritis, 2011
- Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER studyBMC Musculoskeletal Disorders, 2011
- Osteoclastogenesis and arthritisClinical and Experimental Medicine, 2010
- Interleukin-1 is essential for systemic inflammatory bone lossAnnals of the Rheumatic Diseases, 2010
- RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapiesArthritis Research & Therapy, 2009
- Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone lossAnnals of the Rheumatic Diseases, 2009
- A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximabArthritis Research & Therapy, 2007
- Tumour necrosis factor blockade and the risk of osteoporosis: back to the futureArthritis Research & Therapy, 2007
- Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- Arguments for interleukin 1 as a target in chronic arthritisAnnals of the Rheumatic Diseases, 2000